Member Info for B2HS2L

GSA Capital still short.

"Looking forward to October in Germany - cue up the data from the FAP-Dox dose escalation trial, including the longer term follow up data. Key data for the pre|CISION platform #AVCT"

Unclear if the following is the full expectation from CC in October:

From: Trinity Delta: Beneath the tip of the iceberg - 26.06.2025 - https://www.trinitydelta.org/wp-content/uploads/2025/06/Avacta-Update-250626.pdf

"AVA6000 has shown promising early efficacy in SGC, with durable responses (one confirmed partial response, four minor responses), a disease control rate over 90% and median follow up of 5.9 months in the 11 SGC patients enrolled in the Phase Ia cohorts (Exhibit 4).

Median PFS has not yet been reached (vs median PFS of c 3.5 months for conventional therapy in pre-treated SGC).

Additional AVA6000 data in SGC is due late-2025 and will include patients from both Phase Ia (n=11) and Phase Ib (n=30) cohorts.

These data will include cardiac safety and long-term follow up, as cardiotoxicity typically appears post therapy, and long-term follow up will enable Avacta to assess the potential to move beyond the current maximum cumulative doxorubicin exposure of 550mg/m2."

RNS 25.03.2025 - Avacta Announces Completion of the Sale of Launch Diagnostics

Avacta is pleased to announce that all closing conditions to the sale of the entire issued share capital of Launch Diagnostics Holdings Limited and its subsidiaries, its UK-headquartered and largest diagnostics unit, to Duomed Belgium NV, a subsidiary of Palex Healthcare Group S.L.U, have been satisfied and completion of the sale took place yesterday.

++++

BoD badly wants this gone, and will be celebrating getting this item off their To Do List.

If they issued this for Launch, Ditto for Coris.

Completion of the Coris sale is expected in August 2025.

I saw it in an RNS, so it must be kosher.

Investment may be triggered as a result. 😉

This was Shaun Chilton’s opening statement at the AGM recently:

"I think there’ll be a lot of questions around deals, financing, etc., so I’m going to read out a brief statement.

Clearly, there will be time for questions, but it might make things more efficient.

As Chris will outline in her presentation, and as published in this morning’s RNS, Avacta is discussing FAP-Dox with a range of parties.

This is both for separate indications and multiple indications.

We are also delighted to see initial signs of efficacy in both phase 1b indications.

You’re also aware we’re in discussions with the use of pre|CISION as a platform to put through other parties’ payloads.

There’s an incredible amount of interest in AVA6103, or FAP-EXd as we now call it, although the company’s strategy at this point is to protect this asset until we have sight of the initial human data, such is its value."

+++

If a BP decides to bid for Avacta, no matter the size of the offer, from the foregoing Chairman's statement, FOMO will do the rest.

Once data is published (for both phase 1b indications), I don't think Avacta can influence to any great extent when the first bid will fall.

But perhaps AVA6103 entering the clinic, scheduled early next year, will mean the chances of some BP being able to afford Avacta lock stock and barrel diminishes.

I see that situation as being the driver for a prior bid.

Apologies - BP will want to progress things on a bigger budget to a faster timescale should they be successful in an M&A deal, to deliver competitive advantage

Ice, the speed with which Avacta has developed AVA6000 / 6103 is telling.

BH will want to progress things on a bigger budget to a faster timescale should they be successful in an M&A deal, to deliver competitive advantage.

I don't see some of them waiting very much longer, acknowledging some BP have timelines for action sooner than others.

Phase 1b updates will be key trigger points for some BP.

Coris sale is imminent.

From RNS "July 28, 2025 - Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing innovative, targeted oncology drugs, today announced the sale of Coris Bioconcept SRL ("Coris") to 3B BlackBio Dx Ltd for an upfront cash consideration of £2.15 Million (including net cash & customary working capital adjustments) with an additional earn-out based on future business performance of up to £0.615 Million."

Completion of the sale is expected in August 2025, subject to customary closing conditions. (Not too close to BH

...Following the sale of Coris, the Company's cash runway will extend further into Q1 2026.

...Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said:

"This disposal marks the pivotal final step in Avacta's transition to a pure-play therapeutics company...."

+++

I note the use of 'PIVOTAL'. - Let's hope the effects of the sale are also imminent in terms of investment.

+++

Deal is done before the Summer Bank Holiday on Monday 25th August? - More of a hope not an expectation.

Loss making Coris has to be supported financially presently.

A view could be taken that Coris had not long been purchased, when the company changed CEO and immediately wanted out of Diagnostics to create a Therapeutics only business.

Question and Answer session of the Investor Meet presentation – transmitted 06.06.2025 - Brian Hahn:

"drug development is very expensive and the wider net we can cast to attract more capital, the more successful we can make the company."

So far we haven't seen the dragnet the company plans, but their will be some financial sources who require Coris to be history before they invest.

Unclear whether these sources are ready to invest as soon as Coris is sold.

Update from yesterday:

RNS 06.05.2020 - Results for the period ending 31 December 2019

"· An additional pipeline of more than ten pre|CISION chemotherapies has been established... "

This AVA7100 info is not often found elsewhere:

https://avacta.com/wp-content/uploads/2025/06/ARandA.pdf - Page 7

"We believe AVA7100, utilizing our Affimer® proteins, will have the potential to impart tumor-antigen-specific targeting of pre|CISION® drug conjugates with improved pharmacokinetics that will optimize targeting of tumor types that have lower expression of FAP.

We expect to nominate a FAP-targeted Affimer® pre|CISION® product candidate in our AVA7100 program in the second half of 2025 and to advance this program into IND-enabling studies."

On page 4, we see a table identifying potential indications

preCISION FAP affimer AffDC Potential Indications = Head & Neck Squamous cell cancers / Non Small Cell Lung Cancer / Colorectal Cancer

(Warhead not disclosed)

++++

From : AGM Business Update Presentation 02.07.2025 - https://avacta.wistia.com/medias/k6j3aliioe

"Slide 9

We've been asked a lot about what else is in the pipeline. What else are we looking at in terms of precision?

We have disclosed that we've precision enabled a number of warheads.

We have not disclosed what those are.

Ten pre|CISION warheads have been designed and characterized both in vitro and in vivo informed by the FAP docking model.

Together these data have been used to develop our pre|CISION computational design algorithms"

++++

Might some of these ten pre|CISION warheads be in Head & Neck Squamous cell cancers / Non Small Cell Lung Cancer / Colorectal Cancer indications?

🤔

Cj - McNulty being a most likely culprit.

...Think about it this way, there is a ADC beating platform maturing nicely, 2 * preCISION products doing well in early phase 1 trials,

1 * preCISION / Affimer product that has not drawn much attention, but will do an excellent job replacing approved therapeutic products with a short patent.

The company hold the cards, the boards approval must be gained for a positive recommendation to shareholders.

The value of any 1st bid in this scenario is bound to be questioned, and there will be more than one interested party for Avacta when phase1b results are published, because Avacta is an IP rich environment that has long patent lengths.

All areas where some will say true value has not yet been found with a 1st bid.

MM post July 17th 07:31am

The question is do Avacta have any valid preparation / response to a hostile takeover bid.

There are no clues in the Articles of Association.

I have been specifically looking for a Crown Jewels defence, as if any company needs one it's Avacta.

Would Richard Hughes have placed his reputation on the line since joining as an NED without such a defence?

Probably not.

Something must be in place, (and the Chairman has been in this situation before), but of course it's not easily found.

Try posting from the middle of the lake.

The French AF are renowned for their turkey shooting skills.

Ooops - You tend to get what you deserve in life.

- You haven't learnt anything about life since you left infant school, and the resident bully gave you a bloody nose, - just for being you.

You tend to get what you deserve in life.

- You haven't learnt anything about life since you left infant school, and the resident bully gave you a bloody knows, - just for being you.

Ker-ching baby.

Wasn't that the kind of comment you would definitely have challenged just a couple weeks ago?

Steady as she goes.

Do you still have all those shares you bought recently, - didn't think so.

+++

Preliminary Full Year 2024 Results Issued 06.06.2025

Video Presentation https://www.youtube.com/watch?v=ajabya7WHQc

Avacta has a clear value proposition and world-class scientific capabilities and is supported by robust data and an innovative platform and there are good opportunities to attract long-term investors.

The Avacta management team continues to build knowledge and trust with a broad range of specialist and other investors in the US and closer to home.

+++

AGM Business Update Presentation 02.07.2025

Slides: https://avacta.wistia.com/medias/k6j3aliioe

In terms of our funding, we are managing our cash for the R and D pipeline. We are building IP and value. We have realized cash from the sale of Launch.

The Coris divestment is ongoing and near term. We are supported by a number of brokers.

We are broadening our relationships with a wide range of investors, including both UK and US specialists.

+++

The last line shows how hard CC has been working to achieve specialist investor funding since becoming CEO.